Jennison Associates LLC Invests $12.44 Million in DENTSPLY SIRONA Inc. $XRAY

Jennison Associates LLC purchased a new stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the first quarter, HoldingsChannel reports. The institutional investor purchased 1,072,322 shares of the medical instruments supplier’s stock, valued at approximately $12,439,000.

Other hedge funds also recently added to or reduced their stakes in the company. Eurizon Capital SGR S.p.A. purchased a new position in DENTSPLY SIRONA in the 4th quarter worth approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in DENTSPLY SIRONA during the 1st quarter valued at $26,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 2,122 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of DENTSPLY SIRONA by 119.1% in the fourth quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 2,051 shares during the last quarter. Finally, Performa Ltd US LLC raised its stake in shares of DENTSPLY SIRONA by 116.1% in the fourth quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 2,283 shares during the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Mizuho dropped their price objective on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Citigroup started coverage on DENTSPLY SIRONA in a research report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 target price for the company. Barclays dropped their price target on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a report on Thursday, June 4th. UBS Group reduced their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Weiss Ratings cut shares of DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Three research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.42.

Insider Activity at DENTSPLY SIRONA

In other news, Director Brian P. Mckeon bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The stock was bought at an average price of $10.12 per share, with a total value of $101,200.00. Following the acquisition, the director owned 10,000 shares of the company’s stock, valued at approximately $101,200. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael J. Barber purchased 15,175 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $9.88 per share, with a total value of $149,929.00. Following the purchase, the director directly owned 55,943 shares in the company, valued at $552,716.84. This represents a 37.22% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have bought 35,160 shares of company stock worth $351,179. 0.46% of the stock is owned by corporate insiders.

DENTSPLY SIRONA Price Performance

NASDAQ XRAY opened at $13.65 on Wednesday. DENTSPLY SIRONA Inc. has a 12 month low of $9.40 and a 12 month high of $17.09. The stock has a market cap of $2.73 billion, a price-to-earnings ratio of -4.33, a PEG ratio of 1.60 and a beta of 0.89. The company’s 50 day moving average is $10.92 and its two-hundred day moving average is $11.78. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The firm had revenue of $880.00 million during the quarter, compared to the consensus estimate of $841.80 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The business’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current year.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.